Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

  1. Rivera, F.
  2. Massutí, B.
  3. Salcedo, M.
  4. Sastre, J.
  5. Martínez Galán, J.
  6. Valladares-Ayerbes, M.
  7. Serrano, R.
  8. De Paredes, Ma.L.G
  9. Manzano, J.L.
  10. Galán, M.
  11. Alsina, M.
  12. Yuste Izquierdo, A.L.
  13. López, C.
  14. Díaz-Rubio, E.
  15. Conde, V.
  16. Reboredo, M.
  17. Cano, Ma.T.
  18. Pachón, V.
  19. Aranda, E.
Journal:
Cancer Chemotherapy and Pharmacology

ISSN: 1432-0843 0344-5704

Year of publication: 2015

Volume: 75

Issue: 2

Pages: 319-324

Type: Article

DOI: 10.1007/S00280-014-2641-3 GOOGLE SCHOLAR

Sustainable development goals